PubMed Health⌕ Search

Biomedical subjects

Salim Daya

Publications and source records attributed to Salim Daya.

17 recordsLinked to original sources

Methodological issues in infertility research.

It is now well established that clinical decision-making can be enhanced by incorporating evidence from valid studies. This evidence-based approach to health-care management requires a critical appraisal of the available evidence, most of which is of relatively poor quality. If the best evidence is to be put forward to support clinical decisions then it must be derived from studies of high methodological rigour. This chapter discusses important methodological issues affecting the evaluation of the efficacy of therapeutic interventions; these are supplemented with illustrative examples from the literature. These issues form the basis for establishing an approach to inform gynaecological practice, with particular reference to infertility management using assisted reproductive technology and other therapies. Ten important issues are discussed: the formulation of an appropriate research question, the use of randomization, the importance of concealment of treatment allocation, the importance of blinding or masking to avoid ascertainment bias, the avoidance of cointervention, the requirement of an adequate sample size, the restriction of evaluation to the first cycle of treatment, the avoidance of the crossover trial when pregnancy is the outcome of interest, the importance of analysing data using an intention-to-treat approach, and the clear identification of the orientation of the study from the perspectives of superiority, equivalence or non-inferiority of the interventions being compared.

Clinical Trials as Topic↗

Assisted reproductive technologies (ART) in Canada: 2002 results from the Canadian ART Register.

OBJECTIVE: To present the success rates of assisted reproductive technology (ART) cycles performed in 2002 in Canada. This is the second annual report of Canadian ART outcomes. DESIGN: Prospective cohort study. SETTING: Twenty-one of 22 ART centers in Canada. PATIENT(S): Couples undergoing ART treatment in Canada during 2002. INTERVENTION(S): Assisted reproductive technology treatments, including IVF, intracytoplasmic sperm injection (ICSI), frozen embryo transfer (FET), and oocyte donation. MAIN OUTCOME MEASURE(S): Clinical pregnancy, live birth, and multiple birth rates. RESULT(S): A total of 9,188 ART cycles was reported to the Canadian ART Register. There were 6,547 IVF/ICSI cycles using the woman's own oocytes. Per cycle started, the clinical pregnancy rate was 29.9% (36.0% per ET procedure) and the live birth rate was 23.8%; the multiple birth rate per delivery was 34.8%. Of cycles with oocytes retrieved, IVF was performed in 46% and ICSI in 54%; the outcomes were similar with the two procedures. There were 325 IVF/ICSI cycles using donor oocytes. The clinical pregnancy rate was 34.8% and the live birth rate was 24.6%; the multiple birth rate was 34.6%. There were 2,083 FET cycles using the woman's own oocytes. The clinical pregnancy rate was 20.9% and the live birth rate was 16.3%; the multiple birth rate was 25.2%. CONCLUSION(S): For 2002, the Canadian ART Register achieved 95% voluntary participation from Canadian ART centers. Clinical pregnancy and live birth rates comparable to those of other countries were achieved. Success rates were higher in 2002 than in the previous year.

Adult↗

Is there a benefit of low-dose aspirin in assisted reproduction?

PURPOSE OF REVIEW: Assisted reproduction is an effective treatment for infertile women but, despite advances in ovarian stimulation and laboratory techniques, overall pregnancy rates are still relatively low suggesting that methods to improve implantation are required. One strategy is to increase the blood flow to the uterus with low-dose aspirin. The objective of this review is to determine if low-dose aspirin improves clinical pregnancy rates when administered to infertile women undergoing treatment with assisted reproduction. RECENT FINDINGS: A retrospective review was unable to demonstrate improved pregnancy rates when low-dose aspirin was compared with no treatment. Such studies, however, have limited value in clinical decision-making because of poor methodological quality. A recent high-quality randomized, placebo-controlled trial of low-dose aspirin was also unable to demonstrate any benefit, a finding supported by a meta-analysis of 10 trials that collectively had sufficient power to detect a clinically relevant improvement in clinical pregnancy rate. Evidence also exists that low-dose aspirin is potentially harmful, because of increased bleeding problems, miscarriage and congenital anomalies. SUMMARY: Given the lack of efficacy and the potential for harmful effects to both the patient and her offspring, low-dose aspirin should not be administered to infertile women undergoing treatment with assisted reproduction.

Aspirin↗

Life table (survival) analysis to generate cumulative pregnancy rates in assisted reproduction: are we overestimating our success rates?

The variability in the numbers of treatment cycles couples may undertake with assisted reproductive technology (ART) and the length of time they may have to wait between successive cycles of treatment make the evaluation of treatment efficacy and prognosis complicated. The cumulative pregnancy rate using the life table method of analysis is being used more frequently to estimate the effectiveness of treatment. Although this approach is valid in some areas of infertility research, its use in ART is not appropriate, because the factors necessary for the analysis (particularly the scale for measuring the passage of time and lack of informative censoring) are not satisfied. Consequently, an overestimation of the effect of treatment is produced that may lead to biased decision making. Although there is no easy solution to this problem, several options for summarizing the outcome data are offered: pregnancy rate per cycle, time-limited analysis using proportions, conservative cycle-based cumulative pregnancy rate and real-time-based cumulative pregnancy rate. In this manner, more realistic information can be generated to counsel patients, evaluate the efficacy of treatments, compare rates among centres and guide the formulation of policies for infertility management and resource allocation.

Female↗

Evidence-based investigations and treatments of recurrent pregnancy loss.

OBJECTIVE: To give an overview of currently used investigations and treatments offered to women with recurrent pregnancy loss (RPL) and, from an evidence-based point of view, to evaluate the usefulness of these interventions. DESIGN: Ten experts on epidemiologic, genetic, anatomic, endocrinologic, thrombophilic, immunologic, and immunogenetic aspects of RPL discussed methodologic problems threatening the validity of research in RPL during and after an international workshop on the evidence-based management of RPL. CONCLUSION(S): Most RPL patients have several risk factors for miscarriage, and an extensive investigation for all major factors should always be undertaken. There is an urgent need for agreement concerning the thresholds for detecting what is normal and abnormal, irrespective of whether laboratory tests or uterine abnormalities are concerned. A series of lifestyle factors should be reported in future studies of RPL because they might modify the effect of laboratory or anatomic risk factors. More and larger randomized controlled trials, including trials of surgical procedures, are urgently needed, and to achieve this objective multiple centers have to collaborate. Current meta-analyses evaluating the efficacy of treatments of RPL are generally pooling very heterogeneous patient populations and treatments. It is recommended that future meta-analyses look at subsets of patients and treatment protocols that are more combinable.

Abortion, Habitual↗

Assisted reproductive technologies (ART) in Canada: 2001 results from the Canadian ART Register.

OBJECTIVE: To present the success rates of assisted reproductive technologies (ART) cycles performed in 2001 in Canada. DESIGN: Retrospective cohort study. SETTING: Nineteen of 22 ART centers in Canada. PARTICIPANTS: Couples undergoing ART treatment in Canada during 2001. METHODS: Data on each ART cycle performed during 2001 were submitted electronically to the Canadian ART Register (CARTR) by participating centers. MAIN OUTCOME MEASURE(S): Clinical pregnancy and live birth rate per cycle started, multiple birth rate. RESULT(S): A total of 7,884 ART cycles was reported to CARTR. There were 5,393 in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles using the woman's own oocytes. Per cycle started, the pregnancy rate was 28.3%, and the live birth rate was 23.1%; the multiple birth rate per delivery was 32.8%. Of cycles with oocytes retrieved, IVF was performed in 44% and ICSI in 56%; the outcomes were similar with the two procedures. There were 301 IVF/ICSI cycles using donor oocytes. The pregnancy rate was 29.2%, and the live birth rate was 22.4%; the multiple birth rate was 43.5%. There were 1,936 frozen embryo transfer cycles using the woman's own oocytes. The pregnancy rate was 18.9%, and the live birth rate was 15.4%; the multiple birth rate was 24.9%. CONCLUSION(S): For 2001, CARTR achieved 86% voluntary participation from Canadian ART centers. Pregnancy and live birth rates comparable to those of other countries were achieved.

Adult↗

European Classification of Infertility Taskforce (ECIT) response to Habbema et al., 'Towards less confusing terminology in reproductive medicine: a proposal'.

The European Classification of Infertility Taskforce (ECIT) has been formed by ESHRE to develop a set of infertility-related codes (descriptions, interventions and outcomes) appropriate for computerization (http://www.ecit.info). In this article, ECIT reflects on previous suggestions in this Debate series, agreeing with the weaknesses of the current terminology used in reproductive medicine. Although ECIT is enthusiastic about the extension of terminology, caution is raised in abandoning familiar terms that may lead to greater rather than less confusion. Instead, ECIT suggests a way forward using structured computerized statements to retain current terms but extend their meaning.

Europe↗

Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy.

This single centre randomized controlled trial was undertaken to compare the efficacy and safety of clomiphene citrate and low-dose recombinant FSH as first line pharmacological therapy for anovulatory infertility associated with polycystic ovary syndrome (PCOS). Seventy-six infertile patients with PCOS were randomized to receive clomiphene citrate (50-150 mg/day for 5 days) (clomiphene citrate group, n = 38) or recombinant human FSH (FSH group, n = 38) in a chronic, low-dose, step-up protocol (daily starting dose 75 IU) for up to three consecutive cycles. Ovarian response was monitored by transvaginal ultrasonography and human chorionic gonadotrophin (HCG) was given to trigger ovulation in all cycles with appropriate follicular development. The primary outcome measure was cumulative pregnancy after undergoing up to three treatment cycles. Secondary outcomes were cycle cancellation rate, ovulation rate per cycle, cumulative ovulation rate, pregnancy rate per cycle, incidence of OHSS, cumulative live birth rate, and multiple birth rate. One hundred and four clomiphene citrate cycles and 91 FSH cycles were evaluable. The relative risk and its 95% confidence interval were 1.17 (0.97-1.46) for HCG cycles with ovulation, 1.78 (0.92-3.54) for the pregnancy rate per woman, and 1.83 (0.79-4.40) for live births per woman in favour of FSH. The cumulative pregnancy rate after three treatment cycles was 43% with FSH and 24% with clomiphene citrate (P = 0.06). By logistic regression analysis, the factors predicting ovulation included female age, serum androstenedione and use of FSH. Predictors of pregnancy were duration of infertility and use of FSH. This randomized controlled trial suggests that low-dose recombinant FSH may be an effective alternative to clomiphene citrate in first-line treatment for anovulatory PCOS patients. Thus, further studies, possibly multi-centre, in order to avoid problems with patient recruitment, are warranted to confirm these results.

Adult↗

Follicle-stimulating hormone in clinical practice: an update.

Follicle-stimulating hormone (FSH), a glycoprotein produced by the anterior pituitary gland, plays an important role in the regulation of fertility in both men and women. FSH is used clinically to treat women with anovulatory infertility, for controlled ovarian stimulation in women being treated with assisted reproductive technologies (ART), and in the treatment of male hypogonadotrophic hypogonadism. Urine-derived gonadotropin preparations containing variable amounts of FSH together with urinary proteins have been available for many years. More recently, FSH preparations produced using recombinant DNA technology have become available. Recombinant FSH has a high specific activity, high purity, and guaranteed consistency among batches. Two recombinant FSH preparations have been available for clinical use for some years: follitropin-alpha and follitropin-beta. The continuing development of recombinant FSH has recently resulted in a new presentation (follitropin-alpha filled by mass [FbM]). This product can be filled by mass (microg) with an activity (IU), reflecting exceptional consistency as a result of refinement and improvement in the manufacturing process, allowing the clinician to deliver a guaranteed dose of FSH. Experience with recombinant FSH in the treatment of male hypogonadotrophic hypogonadism is limited, but the available data suggest that recombinant FSH has a similar efficacy to urine-derived preparations (urofollitropin). In patients with WHO group I anovulatory infertility, the use of recombinant FSH to stimulate follicular development is effective and well tolerated. In patients with WHO group II anovulation, protocols based on recombinant FSH are more effective than conventional protocols using urofollitropin. Comparative studies and a meta-analysis have shown that recombinant FSH is more effective than urofollitropin for controlled ovarian stimulation in women undergoing ART. Pharmacoeconomic modeling indicates that follitropin-alpha is more cost effective than urofollitropin in a range of different healthcare systems. The available evidence from comparative studies of the two recombinant FSH preparations suggests that follitropin-alpha may have an advantage over follitropin-beta in terms of efficacy. Follitropin-alpha is superior to follitropin-beta in terms of local tolerability. Recent preliminary studies suggest an efficacy advantage for follitropin-alpha FbM compared with standard follitropin-alpha. The FbM presentation appears to represent an advance on standard preparations of recombinant FSH in terms of consistency and clinical efficacy.

Anovulation↗

Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system.

PURPOSE: To evaluate the relative cost-effectiveness of recombinant and urinary follicle-stimulating hormone (FSH) in assisted reproduction techniques in the Spanish National Health Service. METHODS: Markov modelling was used to compare costs and outcomes of three complete treatment cycles using recombinant or urinary FSH for controlled ovarian stimulation. Cost and effectiveness estimates were obtained from the literature and from Spanish clinicians. A Monte Carlo technique was used to randomise the distribution of outcomes at each stage. The analysis was performed by passing a virtual population of 100,000 patients through the computer simulation in each of 5000 Monte Carlo simulations. RESULTS: The cost per pregnancy was Euro12,791+/-1202 ($11,346+/-1066) with recombinant and Euro13,007+/-1319 ($11,537+/-1170) with urinary FSH (p < 0.0001). The mean number of cycles per pregnancy was 4.69 and 5.21, respectively. CONCLUSIONS: Recombinant FSH is more cost-effective than urinary FSH in the Spanish public health care system.

Female↗

Characteristics of good causation studies.

The study of causal relationships is important when addressing questions of efficacy of treatment interventions and etiology of disease. The evaluation of a cause-and-effect relationship between exposure to a putative causal factor and outcome can be undertaken using a variety of study designs including randomized controlled trial and cohort and case control studies. Study participants should be selected in a manner that minimizes bias and confounding and is representative of the target population. Confounding can be controlled by using several strategies including restriction, randomization, stratification, matching, and multivariable analyses. The degree of association is then summarized by the relative risk for prospective studies and the odds ratio for retrospective studies. The precision of these estimates should be indicated by providing their confidence intervals. Important indicators of causation are correct temporal and dose-response relationships between exposure and outcome, a large magnitude in the strength of association, and consistency and specificity of association. Biological and epidemiological sensibility and analogy to other well-established relationships provide additional support for a causal hypothesis.

Bias↗

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States.

OBJECTIVE: To compare the cost effectiveness of recombinant human FSH (Gonal-F; Serono, Inc., Randolph, MA) and urinary FSH (Fertinex; Serono, Inc.) for ovarian stimulation during IVF with or without intracytoplasmic sperm injection for the treatment of infertility. DESIGN: Clinical decision analysis techniques (the Markov model) were used to model the direct medical costs per patient during assisted reproductive technology. MAIN OUTCOME MEASURE(S): Clinical and economic outcomes of two different ovarian stimulation protocols (recombinant human FSH or urinary FSH) during three treatment cycles were considered. RESULT(S): More ongoing pregnancies were achieved, with fewer stimulation cycles, after recombinant human FSH (Gonal-F) than after urinary FSH (Fertinex) (40,665 versus 37,890). In addition, recombinant human FSH was also found to be more cost effective per ongoing pregnancy. From a societal perspective, the mean cost per pregnancy was $40,688 for recombinant human FSH versus $47,096 for urinary FSH. From the insurers' perspective, the mean cost/pregnancy for recombinant human FSH was $28,481 versus $32,967 for urinary FSH. CONCLUSION(S): Recombinant human FSH (Gonal-F) is not only more efficient clinically than urinary FSH (Fertinex), but also more cost effective. This analysis illustrates the point that the economic effectiveness of a drug depends less on its acquisition costs and rather more on the clinical outcomes associated with its use.

Cost-Benefit Analysis↗

Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction.

OBJECTIVE: To determine the relative efficacy of recombinant FSH (rFSH) and urinary FSH (uFSH) for ovarian stimulation in assisted reproductive techniques (ART). DESIGN: Systematic review and meta-analysis of randomized, controlled trials comparing rFSH and uFSH. SETTING: Infertility centers providing treatment with ART. PATIENT(S): Patients undergoing IVF with or without ICSI. INTERVENTION(S): Controlled ovarian stimulation using uFSH or rFSH (follitropin alpha or follitropin beta). MAIN OUTCOME MEASURE(S): Primary: rate of clinical pregnancy per cycle. Secondary: rates of spontaneous abortion, multiple pregnancy, and severe ovarian hyperstimulation syndrome (OHSS); total gonadotropin dose; serum E(2) level and number of follicles at hCG administration; number of oocytes retrieved. RESULT(S): Eighteen trials were included in the meta-analysis. Subgroup analyses demonstrated higher pregnancy rates with both follitropins compared with uFSH. However, statistical significance was reached only in the follitropin alpha versus uFSH comparison in IVF cycles, with an additional pregnancy for every 19 patients treated. Fewer units of rFSH than uFSH achieved the same E(2) level and oocyte yield. No differences were found between treatments in rates of spontaneous abortion, OHSS, and multiple gestation. CONCLUSION(S): rFSH produced higher pregnancy rates per cycle than uFSH when follitropin alpha was used in IVF, and the total gonadotropin dose required was lower.

Abortion, Spontaneous↗